Shares of ChemoCentryx Inc (NASDAQ:CCXI) have been assigned an average broker rating score of 1.67 (Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation and two have assigned a strong buy recommendation to the company.
Analysts have set a twelve-month consensus price target of $13.00 for the company and are expecting that the company will post ($0.22) earnings per share for the current quarter, according to Zacks. Zacks has also given ChemoCentryx an industry rank of 185 out of 265 based on the ratings given to related companies.
Several brokerages recently commented on CCXI. Zacks Investment Research lowered ChemoCentryx from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. ValuEngine lowered ChemoCentryx from a “hold” rating to a “sell” rating in a research note on Friday, November 10th.
ChemoCentryx (NASDAQ:CCXI) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.13. equities research analysts expect that ChemoCentryx will post -0.67 EPS for the current fiscal year.
A number of institutional investors have recently bought and sold shares of the business. Wasatch Advisors Inc. boosted its stake in ChemoCentryx by 10.3% in the second quarter. Wasatch Advisors Inc. now owns 2,255,438 shares of the biopharmaceutical company’s stock worth $21,111,000 after purchasing an additional 210,039 shares in the last quarter. Vanguard Group Inc. boosted its stake in ChemoCentryx by 1.1% in the second quarter. Vanguard Group Inc. now owns 1,212,074 shares of the biopharmaceutical company’s stock worth $11,345,000 after purchasing an additional 13,344 shares in the last quarter. State Street Corp boosted its stake in ChemoCentryx by 7.0% in the second quarter. State Street Corp now owns 429,088 shares of the biopharmaceutical company’s stock worth $4,016,000 after purchasing an additional 27,896 shares in the last quarter. Northern Trust Corp boosted its stake in ChemoCentryx by 9.5% in the second quarter. Northern Trust Corp now owns 276,873 shares of the biopharmaceutical company’s stock worth $2,592,000 after purchasing an additional 24,134 shares in the last quarter. Finally, Iguana Healthcare Management LLC boosted its stake in ChemoCentryx by 10.0% in the third quarter. Iguana Healthcare Management LLC now owns 275,000 shares of the biopharmaceutical company’s stock worth $2,041,000 after purchasing an additional 25,000 shares in the last quarter. 48.65% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/04/zacks-analysts-set-13-00-target-price-for-chemocentryx-inc-ccxi.html.
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.